Clinical trials: Relapsed or Refractory Hodgkin Lymphoma
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory…
- Trial name
- NCT00182637
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
714leukemia, Lymphoma
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00671112
- Testing
- Bortezomib, Everolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Hill, MD, PhD
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 6 sites in Australia, Israel
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back…
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03150329
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Peripheral T-cell Lymphoma
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma…
- Trial name
- PRIMO (NCT03372057)
- Testing
- Duvelisib
- Where
- 36 sites in United States, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- SecuraBio
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
This phase II trial studies how well combination chemotherapy with or without bortezomib works in treating patients with classical Hodgkin lymphoma that has come back or does not respond to prior treatment.
- Trial name
- NCT00967369
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma, Mantle Cell Lymphoma
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas.
- Conditions
- Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma
- Trial name
- NCT06340737
- Testing
- CD22CART Infusion
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Stanford University
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.
- Trial name
- NCT03349281
- Testing
- Pevonedistat, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Julio Barredo, MD
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are…
- Trial name
- SWATCH (NCT05265975)
- Testing
- ATG-010, Lenalidomide, Rituximab
- Where
- 6 sites in China
- Volunteers
- 54 people
- Sponsor
- Antengene Corporation
Non-hodgkin Lymphoma
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
The purpose of this study is to determine the correct dose and safety of adding a new cancer drug, Venetoclax, to a standard combination of chemotherapy drugs used prior to Autologous stem cell transplant (ASCT) in participants…
- Trial name
- NCT03713580
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
- Trial name
- NCT04532203
- Testing
- CAR-T cells, Ommaya Reservoir
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Lymphoma
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
- Trial name
- NCT06733441
- Testing
- TLN-254
- Where
- 5 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Treeline Biosciences, Inc.
Diffuse Large B-cell Lymphoma
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).
- Trial name
- NCT05541328
- Testing
- Tisagenlecleucel
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Novartis Pharmaceuticals
B Cell Lymphoma
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
- Trial name
- NCT06213311
- Testing
- Glofitamab, Obinutuzumab, Axi-cel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell…
- Conditions
- Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04848064
- Testing
- Cyclophosphamide, Fludarabine, Mogamulizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- John Reneau
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00007956
- Testing
- monoclonal antibody mono-dgA-RFB4
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Classical Hodgkin Lymphoma
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial studies how well ibrutinib and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back or has not responded to treatment.
- Trial name
- NCT02940301
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.